TABLE 1.
Patient characteristics at baseline
| Total cohort (n = 48) | |
|---|---|
| Age (years), median (IQR) | 38 (27–48) |
| Men, n (%) | 24 (50.0) |
| Age of onset of AD, n (%) | |
| Childhood | 44 (91.7) |
| Adolescence | 2 (4.2) |
| Adult | 2 (4.2) |
| History of self‐reported episodic acute allergic conjunctivitis, n (%) | 39 (81.3) |
| Allergic asthma, n (%) | 23 (47.9) |
| Allergic rhinitis, n (%) | 36 (75.0) |
| Food allergy, n (%) | 27 (56.3) |
| History of rosacea, n (%) | 2 (4.2) |
| EASI score, median (IQR) | 16.4 (10.9–21.8) |
| IGA score, median (IQR) | 3 (3–4) |
| AD eyelid involvement in the past year, n (%) | 32 (66.7) |
| AD facial involvement in the past year, n (%) | 45 (93.8) |
| TARC (pg./ml), median (IQR) | 1553 (802–2402) |
| Peripheral blood eosinophils (×109/L), median (IQR) | 0.25 (0.15–0.44) |
| Eosinophilia (≥0.45×109/L), n (%) | 11 (22.9) |
| Severity of OSD before the start of dupilumab, a n (%) | |
| No OSD | 5 (10.4) |
| Mild OSD | 19 (39.6) |
| Moderate OSD | 17 (35.4) |
| Severe OSD | 7 (14.6) |
Abbreviations: AD, atopic dermatitis; EASI, Eczema Area and Severity Index; IGA scale, Investigator's Global Assessment Scale; IQR, interquartile range; OSD, Ocular Surface Disease; TARC, thymus and activation‐regulated chemokine.
a
Severity of OSD is based on eye with the highest severity within a patient.